Improving resistance of early stages of Rainbow Trout (Oncorhynchus mykiss) with a novel bacterial solution

by Alexandre Brame, Innovation Manager, Nolivade, Stéphane Frouel, Aquaculture Project Manager and Maxime Hugonin, Aquaculture Product Manager, Mixscience, France

Alexandre Brame, Stephane Frouel and Maxime Hugonin report on a field trial run in France to evaluate the potential of a microbial solution to beneficially modulate microbiome in trout farming system and improve resistance and performance from eggs hatching to early juveniles’ stage of rainbow trout Oncorhynchus mykiss.
 

Among the farmed aquatic species, rainbow trout is one of the most important. Some experts have projected that the world's consumption of rainbow trout will hit 950,000 metric tonnes (mt) annually in the first quarter of 2020 alone. The majority of this volume will be provided by aquaculture, with global sales volume of farmed trout expected to reach roughly 830,000 tonnes (t).

The continued relatively high cost of salmon has seen rainbow trout establish itself as a cheaper alternative fish, offering many of the same health benefits. The specialists predict a compound annual growth rate for worldwide rainbow trout market of approximately five percent over the next 10 years.

However, diseases are a primary problem in trout aquaculture and can severely impact its economic progression in many countries. The development of a fish  disease  is  the result  of  the  interaction   between pathogens,  hosts  and  the environment. Numerous studies have reported that water treatments may be an indirect driver in shaping the bacterial communities of the environment, skin, gills and gastrointestinal tract, commonly referred to as the ‘microbiomes’, of aquatic animals.

Read more, HERE.

The Aquaculturists

---